MINNEAPOLIS, June 11, 2020 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics,
a Bio-Techne brand, has established a new partnership with ZERO –
The End of Prostate Cancer, the leading national nonprofit
organization in the fight against prostate cancer. ZERO advances
research, improves the lives of men and families, and inspires
action for patients, physicians, and advocates involved in the
prostate cancer cause. ZERO offers comprehensive support for
millions of men with prostate cancer, including raising awareness
and education for cutting edge technologies, such as the ExoDx™
Prostate (EPI) test, of interest to patients exploring all of their
options to manage prostate cancer.
One in nine American men will be diagnosed with prostate cancer
during their lifetime. Prostate cancer (PCa) is the second leading
cause of cancer death among American men and is the most commonly
diagnosed cancer. In 2020, it is estimated that 191,930
men will be diagnosed with prostate cancer and more than 33,000 men
will die from the disease. Currently, nearly 3.1 million American
men are living with the disease – more than the population of
Chicago.
The EPI test is a urine-based genomic test that helps inform the
prostate biopsy decision. This liquid biopsy test recently received
coverage for the Veterans Health Administration under the General
Services Administration (GSA) award, received a positive coverage
decision from Medicare, and is included in the National
Comprehensive Cancer Network (NCCN) guidelines for early detection
in men for both initial and repeat biopsy. It is performed by
Exosome Diagnostics in its CLIA, ISO, NY certified and
CAP-accredited laboratory located in Waltham, Massachusetts. The EPI test is a risk
assessment tool that assists physicians and their patients with
determining if a prostate biopsy is needed when presented with an
ambiguous PSA test result, thereby reducing complications from
unnecessary and invasive procedures. ExoDx Prostate is now
available with an At-Home Collection kit, enabling test access to
patients unable to see a healthcare professional or preferring to
collect their sample at-home.
"We are proud to partner with ZERO, an organization that through
its support of prostate cancer research, diagnostics, therapeutics
and patient initiatives has changed the lives of thousands of
prostate cancer patients," said Chuck
Kummeth, Bio-Techne's President and Chief Executive Officer.
"ZERO is an ideal partner to help spread the word about our ExoDx
Prostate (EPI) test and educate men with indeterminate PSA scores
that they can potentially avoid unnecessary biopsy procedures."
"We are excited to join forces with Bio-Techne, an organization
that aligns with our mission, values, and goals. Having a new
diagnostic that can be administered at home is an exciting new
development for patients who face difficult choices managing their
disease, especially during this COVID-19 crisis," said Jamie Bearse, ZERO President & CEO.
ZERO and Exosome Diagnostics will kick off this newly formed
partnership by hosting a Facebook Live broadcast on June 17th at 4:00 p.m. EDT with ZERO President & CEO,
Jamie Bearse and Urology expert, Dr.
Ali Kasraeian. The event will be
broadcast live and will be available for replay on the ExoDx
Prostate Test Facebook page
(https://www.facebook.com/ExoDxProstateTest/) and on the Zero – The
End of Prostate Cancer page (https://www.facebook.com/ZeroCancer/)
and on ZERO's Youtube channel. Mr. Bearse and Dr. Kasraeian will
discuss current challenges in prostate cancer management and how
this is changing during the COVID-19 era where patients and their
physicians are adjusting to new rules and regulations. Members will
have the opportunity to address questions directly to either Dr.
Kasraeian or Mr. Bearse. To see the broadcast tune in on Facebook
at 4:00PM Eastern Time.
About Bio-Techne Corporation (NASDAQ:TECH)
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and
manufacturer of high-quality purified proteins and reagent
solutions - notably cytokines and growth factors, antibodies,
immunoassays, biologically active small molecule compounds, tissue
culture reagents, T-Cell activation and gene editing technologies.
Bio-Techne's product portfolio also includes protein analysis
solutions, sold under the ProteinSimple brand name, offering
researchers efficient and streamlined options for automated Western
blot and multiplexed ELISA workflow. These reagent and protein
analysis solutions are sold to biomedical researchers as well as
clinical research laboratories and constitute the Protein Sciences
Segment. Bio-Techne also develops and manufactures diagnostic
products including FDA-regulated controls, calibrators, blood gas
and clinical chemistry controls and custom assay development on
dedicated clinical instruments. Bio-Techne's genomic tools include
advanced tissue-based in situ hybridization assays (ISH) for
research and clinical use, sold under the ACD brand as well as a
portfolio of clinical molecular diagnostic oncology assays,
including the ExoDx® Prostate test for prostate cancer diagnosis.
These diagnostic and genomic products comprise Bio-Techne's
Diagnostics and Genomics Segment. Bio-Techne products are integral
components of scientific investigations into biological processes
and molecular diagnostics, revealing the nature, diagnosis,
etiology and progression of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated approximately $714
million in net sales in fiscal 2019 and has over 2,200
employees worldwide.
Contact: David Clair, Senior
Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About ZERO — The End of Prostate Cancer
ZERO — The End of Prostate Cancer is the leading national
nonprofit with the mission to end prostate cancer. ZERO advances
research, improves the lives of men and families, and inspires
action. We're building Generation ZERO, the first generation of men
free from prostate cancer, through our national run/walk series,
education and patient support programs, and grassroots advocacy.
ZERO is a 501(c)(3) philanthropic organization recognized with four
out of four stars by Charity Navigator, accredited by the Better
Business Bureau, with regional chapters across the country. We
dedicate 86 cents of every dollar to research and programs. For
more information, visit www.zerocancer.org.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bio-techne-and-zero--the-end-of-prostate-cancer-announce-partnership-to-fund-education-and-awareness-campaigns-to-empower-men-with-prostate-cancer-301074074.html
SOURCE Bio-Techne Corporation